Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients

被引:21
|
作者
Toth, Kinga [1 ]
Patai, Arpad V. [1 ]
Kalmar, Alexandra [1 ,2 ]
Bartak, Barbara Kinga [1 ]
Nagy, Zsofia Brigitta [1 ]
Galamb, Orsolya [2 ]
Wichmann, Barnabas [2 ]
Tulassay, Zsolt [1 ,2 ]
Molnar, Bela [1 ,2 ]
机构
[1] Semmelweis Univ, Dept Internal Med 2, Szentkiralyi Utca 46, H-1088 Budapest, Hungary
[2] Hungarian Acad Sci, Mol Med Res Unit, Budapest, Hungary
关键词
SEPT9; Colorectal cancer; Tumormarkers; Circadian rhythm; Cell-free DNA; BREAST-CANCER; CLOCK; PLASMA; BLOOD; PROGRESSION; EXERCISE; INFLAMMATION; CORTISOL; BEHAVIOR; SLEEP;
D O I
10.1007/s12253-016-0174-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To determine the level of cell-free DNA (cfDNA), Septin 9 (SEPT9) and tumor markers (CEA, AFP, CA19-9, TPA, CA72-4). Plasma samples were collected four times a day (06:00, 12:00, 18:00, 24:00) from 9 patients with CRC (5 stage I-II, 4 stage III-IV), from one with colorectal adenoma and from one healthy control. CfDNA was isolated, quantified and bisulfite-converted. CfDNA and methylated SEPT9 were determined by RT-PCR. Plasma levels of conventional tumor markers were also measured. The lowest cfDNA concentrations were observed at 24:00 and 18:00 in stage I-III patients. In stage IV samples low cfDNA level (mean 48.2 ng/ml) were observed at several time points (6:00, 12:00, 18:00). The highest cfDNA levels were measured at 6:00 and 12:00 in CRC I-III stages and at 24:00 in stage IV samples (78.65 ng/ml). Higher in-day differences were found in stage II (43-48%) than in stage I samples (22%). Interestingly, the highest SEPT9 methylation level was found at 24:00 in most CRC cases, in contrast to the cfDNA levels. At 24:00, all cancer and adenoma cases were positive for SEPT9 methylation. At other time points (6:00, 12:00, 18:00) only 77.7% of CRC samples showed SEPT9 positivity. Stage I samples were SEPT9 positive only at 24:00. CEA and CA19-9 levels displayed correlation with the amount of cfDNA in case of late stage cases. Daytime activity can influence SEPT9 positivity in cases with low concentration of cfDNA. Thus, it may improve screening sensitivity by collecting samples earlier in the morning.
引用
收藏
页码:699 / 706
页数:8
相关论文
共 50 条
  • [21] Plasma-based methylated SEPTIN9 circulating tumor DNA to predict progression-free and overall survival in metastatic colorectal cancer
    Hitchins, Megan Philippa
    Aguirre, Francesca Paola
    Alvarez, Rocio
    Zhou, Lisa
    Gangi, Alexandra
    Hendifar, Andrew Eugene
    Kim, Sungjin
    Diniz, Marcio A.
    Gong, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer
    Fu, Bo
    Yan, Peng
    Zhang, Shan
    Lu, Yan
    Pan, Li
    Tang, Wenqiang
    Chen, Shen
    Chen, Shuangfeng
    Zhang, Anqi
    Liu, Wei
    DISEASE MARKERS, 2018, 2018
  • [23] Methylated Septin 9 DNA: a biomarker found in blood plasma, for the detection of colorectal cancer.
    deVos, T.
    Lofton-Day, C.
    Model, F.
    Sledziewski, A.
    Liebenberg, V.
    Day, R.
    CLINICAL CHEMISTRY, 2007, 53 (06) : A109 - A109
  • [24] Detection of Colorectal Cancer in Circulating Cell-Free DNA by Methylated CpG Tandem Amplification and Sequencing
    Li, Jingyi
    Zhou, Xin
    Liu, Xiaomeng
    Ren, Jie
    Wang, Jilian
    Wang, Wendong
    Zheng, Yuxuan
    Shi, Xinyun
    Sun, Tao
    Li, Zhifei
    Kang, Anding
    Tang, Fuchou
    Wen, Lu
    Fu, Wei
    CLINICAL CHEMISTRY, 2019, 65 (07) : 916 - 926
  • [25] Detection of tumor progression via cell-free DNA (cfDNA) in patients with colorectal cancer.
    Mende, Marika
    Thiede, Christian
    Schuster, Caroline
    Aust, Daniela Ellen
    Folprecht, Gunnar
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [26] Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden
    Bhangu, Jagdeep Singh
    Taghizadeh, Hossein
    Braunschmid, Tamara
    Bachleitner-Hofmann, Thomas
    Mannhalter, Christine
    SURGICAL ONCOLOGY-OXFORD, 2017, 26 (04): : 395 - 401
  • [27] Cell-free DNA for Colorectal Cancer Screening
    Lo, Y. M. Dennis
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (11): : 1047 - 1050
  • [28] Colorectal Cancer: Analysis of cell-free Tumor DNA allows Therapy Monitoring
    Lorenz, Judith
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2019, 57 (02): : 120 - +
  • [29] Clinical Utility of a Cell-Free DNA Assay in Patients With Colorectal Cancer
    Chan, Ren-Hao
    Lin, Peng-Chan
    Chen, Shang-Hung
    Lin, Shao-Chieh
    Chen, Po-Chuan
    Lin, Bo-Wen
    Shen, Meng-Ru
    Yeh, Yu-Min
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [30] Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer
    Schwarzenbach, Heidi
    Stoehlmacher, Jan
    Pantel, Klaus
    Goekkurt, Eray
    CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM V, 2008, 1137 : 190 - 196